Insulin is an important agent for the treatment of diabetes mellitus (DM). Allergic reactions to insulin therapy, although rare, have been evident since animal insulin became available for the treatment of DM in 1922. Hypersensitivity to insulin has considerably been reduced with the introduction of human insulin produced by recombinant deoxyribonucleic acid technology. Here, we present a case of Type 2 DM who demonstrated immediate (Type 1) hypersensitivity reaction on the sites of subcutaneous injection of soluble and isophane insulin but insulin glargine was tolerated well and provided good glycemic control.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4386139 | PMC |
| http://dx.doi.org/10.4103/0253-7613.153438 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A national survey on registered products, availability, prices, and affordability of 100 essential medicines in community pharmacies across Sri Lanka.
BMC Health Serv Res
October 2023
Department of Pharmacology, Faculty of Medicine, University of Colombo, 25 Kynsey Rd, Colombo, 00800, Sri Lanka.
Introduction: Availability of essential medicines that meet the expected quality standards, in appropriate dosage forms at affordable prices is a fundamental prerequisite to fulfill healthcare needs of given a population. This study assessed available products, prices and affordability of essential medicines (EM) in community pharmacies in Sri Lanka with comparison of registration status from the National Medicines Regulatory Authority(NMRA).
Methods: A cross-sectional island-wide survey of 80 pharmacies was conducted according to World Health Organization and Health Action International Manual (WHO/HAI).
Modeling of Pharmacokinetic Profiles of Insulin Aspart and Biphasic Insulin Aspart 30/70.
J Clin Pharmacol
September 2022
Department of Clinical Pharmacology, Yaroslavl State Medical University, Yaroslavl, Russia.
This study includes modeling and simulation of insulin aspart pharmacokinetics (PK). The authors used PK data of biosimilar insulins-insulin aspart and biphasic insulin aspart 30/70-to develop a predictive population PK model for the insulins. The model was built via Monolix software, taking into account the weight-based dosing and the dose and body-weight effects on the parameters.
View Article and Find Full Text PDFHighly sensitive endotoxin detection using a gold nanoparticle loaded layered molybdenum disulfide-polyacrylic acid nanocomposite.
Analyst
June 2020
Nanoscience Research Laboratory, School of Materials Science and Engineering, National Institute of Technology, Calicut-673601, Kerala, India.
Endotoxins or lipopolysaccharides (LPS) are pathogens released from the outer membrane of gram-negative bacteria which produce toxic effects on humans. The sensitive and selective detection of LPS is in high demand, especially in the field of medical supplies, therapeutics and in the food industry. Herein we report a new nano-probe based on a gold nanoparticle loaded, water-soluble layered molybdenum disulfide-polyacrylic acid (Au/MoS-PAA) nanocomposite as a label-free voltammetric aptasensor for ultrasensitive LPS detection.
View Article and Find Full Text PDFLower rates of hypoglycemia during maintenance treatment with insulin degludec/insulin aspart versus biphasic insulin aspart 30: a combined analysis of two Phase 3a studies in type 2 diabetes.
J Diabetes
September 2016
University of Sydney, Royal North Shore Hospital, Sydney, New South Wales, Australia.
Background: Insulin degludec/insulin aspart (IDegAsp) is a soluble coformulation of the basal analog insulin degludec and the rapid-acting prandial insulin aspart in a single injection. The present combined analysis of two Phase 3a trials compared the incidence of hypoglycemia in participants treated twice daily with IDegAsp or biphasic insulin aspart 30 (BIAsp 30).
Methods: Hypoglycemia data were analyzed from two similarly designed randomized controlled open-label treat-to-target Phase 3a clinical trials of adults with type 2 diabetes (T2D).
Aim: To evaluate the efficacy and safety of twice-daily insulin degludec/insulin aspart vs. twice-daily biphasic insulin aspart 30 in people with Type 2 diabetes mellitus who were naïve to insulin.
Methods: In this 26-week, multinational, open-label, controlled, two-arm, parallel-group, treat-to-target trial, participants [mean (± sd) age 58.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!